Study Feasibility and Site Selection

Checklist for Assessing Clinical Site Capabilities

Posted on digi By digi

Evaluating site capabilities is a critical component of clinical trial feasibility and site selection. Regulatory authorities, including the FDA and EMA, expect sponsors and CROs to assess and document a site’s ability to conduct the trial in accordance with protocol, GCP guidelines, and regulatory requirements. An incomplete or rushed site capability assessment can lead to trial delays, protocol deviations, and inspection findings.
Click to read the full article.

Site Capability Assessment, Study Feasibility and Site Selection

Assessing Staff Competency and Site Infrastructure

Posted on digi By digi

Assessing the competency of site staff and the adequacy of site infrastructure is a cornerstone of clinical trial feasibility planning. Regulatory bodies, including the FDA, EMA, and MHRA, expect sponsors and CROs to verify that trial sites are equipped—both in terms of people and facilities—to conduct a study in compliance with protocol and Good Clinical Practice (GCP).
Click to read the full article.

Site Capability Assessment, Study Feasibility and Site Selection

Evaluating Site SOPs for Trial Readiness

Posted on digi By digi

Standard Operating Procedures (SOPs) are essential components of a clinical trial site’s quality system. They provide documented instructions for critical trial activities such as informed consent, investigational product (IP) handling, adverse event (AE) reporting, source data documentation, and data entry. For sponsors and CROs conducting feasibility assessments, evaluating a site’s SOP portfolio offers key insights into trial readiness, GCP compliance, and operational maturity.
Click to read the full article.

Site Capability Assessment, Study Feasibility and Site Selection

Technology Readiness Evaluation of Trial Sites

Posted on digi By digi

As clinical trials increasingly rely on electronic data capture (EDC), eConsent platforms, remote monitoring, and decentralized trial models, the technology readiness of clinical trial sites has become a critical factor in feasibility and site selection. Traditional site capability assessments focused on physical infrastructure and human resources, but now must be expanded to evaluate IT systems, connectivity, digital compliance, and readiness for electronic workflows.
Click to read the full article.

Site Capability Assessment, Study Feasibility and Site Selection

Documenting Site Capabilities in Regulatory Submissions

Posted on digi By digi

As regulatory expectations evolve, sponsors are increasingly required to justify and document the selection of clinical trial sites in regulatory submissions. Whether submitting to the FDA, EMA, MHRA, PMDA, or CDSCO, demonstrating that each selected site is qualified, equipped, and capable of conducting the proposed study is a key part of compliance and inspection readiness.
Click to read the full article.

Site Capability Assessment, Study Feasibility and Site Selection

Balancing Cost and Capability in Site Selection

Posted on digi By digi

Clinical trial sponsors and CROs face a critical decision when selecting investigator sites: how to balance operational capability with financial cost. A site with advanced infrastructure, highly experienced investigators, and strong historical performance may command a premium budget. Conversely, lower-cost sites may present challenges in enrollment, protocol compliance, or data quality. Selecting the right mix of cost-efficient and high-performing sites is essential for trial success, budget control, and timely regulatory submission.
Click to read the full article.

Site Capability Assessment, Study Feasibility and Site Selection

Conducting On-Site Capability Audits

Posted on digi By digi

Before initiating a clinical trial at an investigator site, sponsors and CROs must assess whether the site is operationally ready and compliant with GCP and regulatory expectations. While feasibility questionnaires and remote assessments are important, on-site capability audits—also known as pre-study visits (PSVs) or site qualification visits—provide a firsthand evaluation of infrastructure, documentation, staffing, SOPs, and past performance. These audits are critical to ensuring that selected sites can execute the protocol safely, efficiently, and in accordance with local and international regulations.
Click to read the full article.

Site Capability Assessment, Study Feasibility and Site Selection

Common Red Flags in Capability Assessments

Posted on digi By digi

Clinical trial success depends heavily on selecting qualified, reliable, and compliant investigator sites. The feasibility and site capability assessment process is designed to evaluate a site’s readiness before study activation. However, sponsors and CROs must go beyond standard questionnaires and proactively identify red flags that signal potential risk. These indicators—whether related to infrastructure, staffing, past performance, or regulatory behavior—can help prevent costly protocol deviations, enrollment failures, or inspection findings later in the trial.
Click to read the full article.

Site Capability Assessment, Study Feasibility and Site Selection

Remote Methods for Evaluating Site Capabilities

Posted on digi By digi

The COVID-19 pandemic accelerated the adoption of remote and digital approaches in clinical research operations, including feasibility assessments and site qualification. Even post-pandemic, the use of remote methods to evaluate clinical site capabilities remains highly relevant due to cost savings, operational flexibility, and global trial complexity. Sponsors and CROs now conduct virtual site evaluations using teleconferencing, document sharing platforms, e-questionnaires, and remote facility walkthroughs to determine site readiness for clinical trials.
Click to read the full article.

Site Capability Assessment, Study Feasibility and Site Selection

Integrating Site Capability Data into Trial Planning Systems

Posted on digi By digi

Site capability assessments generate vast volumes of operational and compliance data critical to clinical trial success. Yet, in many organizations, this data remains siloed in spreadsheets, email attachments, and disconnected feasibility questionnaires. Integrating structured site capability data into centralized trial planning systems—like Clinical Trial Management Systems (CTMS), feasibility platforms, and trial analytics dashboards—is essential to optimize site selection, improve forecasting, enhance compliance, and accelerate study startup.
Click to read the full article.

Site Capability Assessment, Study Feasibility and Site Selection